Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PHERFLOT perioperative pembrolizumab + trastuzumab + FLOT for HER2-positive localized esophagogastric adenocarcinoma
2024-513610-34-00Phase 2Completed
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- Oct 2024
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab, trastuzumab, docetaxel, oxaliplatin, folinic acid and 1 more in gastroesophageal junction adenocarcinoma and gastric adenocarcinoma, sponsored by Institut für Klinische Krebsforschung. Primary endpoints: Disease-free survival and Pathological complete response rate. Started Oct 2024; status: completed.
02
Drugs
03
Conditions
gastroesophageal junction adenocarcinomagastric adenocarcinoma
Beyond the preview
Go deeper on 2024-513610-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513610-34-00.